Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists.
Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low platelet counts after chemotherapy. As little is known regarding the possible activation of platelets by thrombopoietin, we examined the effects of thrombopoietin on platelet aggregation induced by shear stress and various agonists in native plasma. Using hirudin as an anticoagulant, thrombopoietin (1 to 100 ng/mL) enhanced platelet aggregation induced by 2 micromol/L adenosine-diphosphate (ADP) in a dose dependent fashion. The enhancement was not affected by treatment of platelets with 1 mmol/L aspirin plus SQ-29548 (a thromboxane antagonist, 1 micromol/L) but was inhibited by a soluble form of the thrombopoietin receptor, suggesting that the enhancement was mediated by the specific receptors and does not require thromboxane production. Epinephrine (1 micromol/L), which does not induce platelet aggregation in hirudin platelet rich plasma (PRP), did so in the presence of thrombopoietin (10 ng/mL). Thrombopoietin (10 ng/mL) also enhanced or primed platelet aggregation induced by collagen (0.5 micron.mL),. thrombin, serotonin, and vasopressin. Thrombopoietin does not induce any rise in cytosolic ionized calcium concentration nor activation of protein kinase C, as estimated by phosphorylation of preckstrin, indicating that the priming effects of thrombopoietin does not require those processes. The ADP- or thrombin-induced rise in cytosolic ionized calcium concentration was not enhanced by thrombopoietin (100 ng/mL). Further, shear (ca. 90 dyn/cm2)-induced platelet aggregation was also potentiated by thrombopoietin. The priming effect on epinephrine-induced platelet aggregation in hirudin PRP was unique to thrombopoietin, with no effects seen using interleukin-6 (IL-6), IL-11, IL-3, erythropoietin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, or c-kit ligand. These data indicate that monitoring of platelet functions may be necessary in the clinical trials of thrombopoietin.
Oda
A
A
Division of Hematology, Department of Internal Medicine, Keio University, Tokyo, Japan.
Miyakawa
Y
Y
Druker
B J
BJ
Ozaki
K
K
Yabusaki
K
K
Shirasawa
Y
Y
Handa
M
M
Kato
T
T
Miyazaki
H
H
Shimosaka
A
A
Ikeda
Y
Y
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001809:Blood Viscosity / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003094:Collagen / Q000494:pharmacology; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D007378:Interleukins / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013314:Stress, Mechanical; D013917:Thrombin / Q000494:pharmacology; D013926:Thrombopoietin / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology
D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D016298:Hematopoietic Cell Growth Factors; D006629:Hirudins; D006834:Hydrazines; D007378:Interleukins; D009842:Oligopeptides; D011994:Recombinant Proteins; D014667:Vasopressins; D012701:Serotonin; D000244:Adenosine Diphosphate; C045749:SQ 29548; D003094:Collagen; D013926:Thrombopoietin; C046617:arginyl-glycyl-aspartyl-serine; D013917:Thrombin; D004837:Epinephrine